北京怡和嘉业医疗科技股份有限公司 关于举行2023年半年度网上业绩说明会的公告 证券代码：301367 证券简称：怡和嘉业 公告编号：2023-059 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日发 布了《2023 年半年度报告》及其摘要，并披露于中国证监会指定的创业板信息披露网站 巨潮资讯网（http://www.cninfo.com.cn）。 1 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 为便于广大投资者更深入全面地了解公司情况，公司定于 2023 年 8 月 17 日（星期 四）下午 15:00-16:30 在深圳证券交易所"互动易"平台"云访谈"栏目举行 2023 年半 年度网上业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆深圳 证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业 绩说明会。 出席本次业绩说明会的人员拟定为：公司董事长兼总经理庄志先生、独立董事库逸 轩先生、副总 ...

证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------|----------------| | | | 编号：2023—008 | | | □ 分析师会议 | | | 投资者关系活动 | □ 业绩说明会 | | | 类别 | □ 路演活动 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 参与单位名称及 | | | | 人员姓名 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 中融汇信期货 李兆达 | --- | --- | |----------------|-------------------------------------------| | | 中信资管 于质冰 | | | 中金资管孟 繁卓 | | | 中信建投资管 鲍冲 ...

证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | |----------------| | | | 投资者关系活动 | | 类别 | | | | | | | | | | | | 主持人 | | | | | | | | | | 时间 2023 | | | | 上市公司接待人 | 员姓名 投资者关系：郭宝泽 会议开始前，公司董事长庄志博士对公司第三届董事会、监 事会换届选举及高管任命事项进行了说明： 投资者关系活动 今天公司完成了第三届董事会、监事会的换届选举，并任命 主要内容介绍 了新一届管理层，本次换届选举适应了公司上市后业务发展需 要。 新一届董事会、监事会及管理层成员在公司平均任职时间已 超 15 年，对公司情况较为了解，事实上，在本次换届任命前， 部分人员已经在履行高管职能，本次正式换届任命将有利于公司 整个管理层更加稳定，激活公司内生动力，促进公司持续稳定发 展。 投资者提问及公司回复主要情况如下： 1、请问公司 5 月份出口数据如何？目前市场上流传着注册 地在北京的呼吸机企业 5 月份的海关出口数据，是否与公司出 口数据吻合？ 公司产 ...

证券代码：301367 证券简称：怡和嘉业 | --- | --- | |----------------|--------------------| | | □ | | 投资者关系活动 | □ | | 类别 | □ | | | □ 现场参观 | | | √ 其他 | | | 中金公司 | | | 中信建投 | | | 太平洋证券 | | | 国联证券 | | 主持人 | | | | 海通证券 | | | 中信证券 | | | 兴业证券 | | | 长江证券 | | 时间 2023 | 年 6 月 | | | 地点 公司会议室 | | | 董事长：庄志 | | 上市公司接待人 | | | | 董事会秘书：张晓超 | | 员姓名 | | | | 投资者关系：郭宝泽 | | | | | | | | 投资者关系活动 | | | 主要内容介绍 | | | | | | | 事项尚需公司 | | | 效。 | 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | |------------------------------------------------------------| | 本次董事会换 ...

证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | |----------------|-----------------------| | | □ 特定对象调研 □ | | 投资者关系活动 | □ 媒体采访 □ | | 类别 | □ 新闻发布会 □ | | | □ 现场参观 | | | √ 其他 | | | 中金公司 邹 | | | 中信建投 | | | 太平洋证券 张世杰、罗 | | 主持人 | 国联证券 郑 | | | 海通证券 | | | 中信证券 陈 | | | 兴业证券 | | | 长江证券 | | 时间 2023 | 年 5 月 29 日 | | | 地点 公司会议室 | | | 董事长：庄志 | | 上市公司接待人 | | | | 董事会秘书：张晓超 | | 员姓名 | 投资者关系：郭宝泽 | | | | | | | | | | | 投资者关系活动 | | | 主要内容介绍 | | | | | | | | | | 步人选。 | 投资者提问及公司回复主要情况如下： | --- | |------------------- ...

Financial Performance - The company's revenue for Q1 2023 reached ¥480,444,800.79, representing a 131.85% increase compared to ¥207,219,563.77 in the same period last year[4] - Net profit attributable to shareholders was ¥155,448,543.29, up 192.03% from ¥53,229,648.40 year-on-year[4] - Basic earnings per share rose to ¥2.43, reflecting a growth of 118.92% from ¥1.11 in the previous year[4] - Operating profit for Q1 2023 was ¥183,623,653.85, compared to ¥60,940,217.22 in Q1 2022, reflecting a growth of approximately 201%[20] - Net profit for Q1 2023 was ¥156,867,930.24, up from ¥53,229,648.40 in Q1 2022, representing an increase of about 195%[20] - Total comprehensive income attributable to minority shareholders for Q1 2023 is CNY 1,419,386.95, compared to CNY 0.00 in the previous period[21] - Basic and diluted earnings per share for Q1 2023 are both CNY 2.43, up from CNY 1.11 in the previous period, representing a 118.02% increase[21] Cash Flow - The net cash flow from operating activities was ¥76,241,811.79, an increase of 86.04% compared to ¥40,981,230.93 in Q1 2022[4] - Cash inflow from operating activities for Q1 2023 is CNY 435,919,191.93, a 95.00% increase from CNY 223,448,045.68 in the previous period[22] - Cash inflow from investment activities is CNY 1,581,783,945.90, significantly higher than CNY 280,354,022.48 in the previous period[23] - Cash outflow for investment activities totals CNY 1,692,097,686.36, compared to CNY 292,770,161.18 in the previous period[23] - Net cash flow from investment activities is -CNY 110,313,740.46, worsening from -CNY 12,416,138.70 in the previous period[23] - The company reported a net decrease in cash and cash equivalents of CNY 38,966,031.80 for Q1 2023[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,030,277,087.50, a 3.52% increase from ¥2,927,378,559.21 at the end of 2022[4] - Total liabilities decreased to ¥256,428,994.26 in Q1 2023 from ¥310,398,396.21 in the same period last year[17] - As of March 31, 2023, the company's total current assets amounted to ¥2,932,115,882.67, an increase from ¥2,848,918,930.94 at the beginning of the year, representing a growth of approximately 2.9%[15] - The company's cash and cash equivalents decreased to ¥317,147,107.19 from ¥356,113,138.99, reflecting a decline of about 10.9%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,040[10] - The largest shareholder, Zhuang Zhi, holds 13.10% of shares, totaling 8,383,291 shares[10] - The second-largest shareholder, Zhuhai Hexuan Investment Center, holds 12.45%, amounting to 7,968,347 shares[10] - The third-largest shareholder, Chen Bei, owns 9.25% of shares, which is 5,917,948 shares[10] - The total number of shares held by the top ten shareholders represents a significant portion of the company's equity[10] - The largest foreign shareholder, Nengjin Co., Ltd., holds 6.00% of shares, equating to 3,838,225 shares[10] - The top ten shareholders include a mix of individual and institutional investors, indicating diverse ownership[10] - The report highlights that Zhuang Zhi and Xu Jian are acting in concert, which may influence shareholder dynamics[11] Research and Development - Research and development expenses increased by 76.35% to ¥19,539,134.96, driven by higher investment in R&D[9] - Research and development expenses for Q1 2023 were ¥19,539,134.96, up from ¥11,079,796.79 in Q1 2022, indicating a focus on innovation[20] Market Strategy - The company continues to focus on expanding its market presence and developing new technologies in the medical sector[14]

北京怡和嘉业医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2023 年 3 月 30 日发 布了《2022 年年度报告》及其摘要，并披露于中国证监会指定的创业板信息披露网站巨 潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者更深入全面地了解公司情况，公司定于 2023 年 4 月 13 日（星期 四）15:00-16:00 在全景网举办 2022 年度业绩说明会，本次业绩说明会将采用网络远程 的方式举行，投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 业绩说明会。 出席本次业绩说明会的人员拟定为：公司董事长庄志先生、董事兼总经理高成伟先 生、董事兼副总经理许坚先生、董事会秘书张晓超先生、财务总监戚余光先生、独立董 事孙培睿先生。具体以当天实际参加会议人员为准。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向广大投资 者公开征集问题，投资者可于 202 ...

Financial Performance - The company's operating revenue for 2022 reached ¥1,415,367,125.64, representing a 113.64% increase compared to ¥662,500,356.97 in 2021[22]. - Net profit attributable to shareholders was ¥380,289,696.80, a significant increase of 161.04% from ¥145,681,330.12 in the previous year[22]. - The basic earnings per share for 2022 was ¥7.51, up 147.04% from ¥3.04 in 2021[22]. - The total assets of the company at the end of 2022 amounted to ¥2,927,378,559.21, reflecting a 369.36% increase from ¥623,691,613.69 at the end of 2021[22]. - The company generated operating cash flow of ¥375,209,139.78 in 2022, which is a 259.39% increase compared to ¥104,401,485.06 in 2021[22]. - The company reported a weighted average return on equity of 39.16% for 2022, an increase of 5.13% from 34.03% in 2021[22]. - The company’s net profit after deducting non-recurring gains and losses was ¥364,768,172.83, up 169.81% from ¥135,194,779.70 in 2021[22]. - The company achieved a revenue of 1,415.37 million yuan, representing a year-on-year growth of 113.64%[72]. - The net profit attributable to shareholders reached 380.29 million yuan, with a year-on-year increase of 161.04%[72]. - Total revenue for 2022 reached ¥1,415,367,125.64, a 113.64% increase compared to ¥662,500,356.97 in 2021[74]. Market Overview - The global medical device market is projected to grow from $48.54 billion in 2020 to $68.36 billion by 2025, indicating a strong demand for medical devices[34]. - The company operates in the medical device industry, focusing on respiratory health products, which are expected to see increased demand due to the aging population and rising chronic disease rates[33]. - The Chinese medical device market grew from RMB 370 billion in 2016 to RMB 770.1 billion in 2020, with a CAGR of 20.1%[35]. - The home medical device market in China reached RMB 239.5 billion in 2020, expected to grow to RMB 463.8 billion by 2025, at a CAGR of 14.1%[35]. - The prevalence of chronic obstructive pulmonary disease (COPD) in China was approximately 105 million in 2020, with a diagnosis rate of only 26.8%[37]. Product Development and R&D - The company is committed to independent research and development, maintaining a strong capability to develop core technologies for its main products[53]. - The company has established multiple R&D teams for different product lines, focusing on home non-invasive ventilators, consumables, and medical respiratory diagnostic products[58]. - The company has implemented a reward system to encourage R&D personnel and promote innovation through patent achievements[59]. - The company has established a comprehensive R&D innovation system with experienced personnel across multiple locations, enhancing its competitive advantage[65]. - The company is focused on expanding its product matrix through continuous innovation in hardware design and algorithm development[67]. Corporate Governance - The company has implemented a robust corporate governance structure, ensuring compliance with relevant laws and regulations to promote sustainable and high-quality development[146]. - The board of directors consists of 9 members, including 3 independent directors, ensuring adherence to governance standards and protecting shareholder rights[149]. - The company has established a performance evaluation and incentive mechanism for its directors and senior management, promoting transparency and accountability[151]. - The company actively engages in investor relations, ensuring timely and accurate information disclosure to all shareholders[153]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, and operations, ensuring a self-sufficient business model[155]. Risk Management - The company faces market competition risks as many players enter the respiratory health device sector, highlighting the need for differentiation beyond price advantages[138]. - The company is exposed to risks related to intellectual property, including potential infringement claims that could lead to financial burdens and hinder product development and sales[140]. - The company relies on a diverse network of distributors, which poses risks in maintaining stable relationships and could impact sales stability and revenue growth[141]. - The company faces regulatory and liability risks in overseas markets, which could adversely affect its reputation and business operations if disputes arise[142]. Future Outlook - The company has set a revenue guidance of 1.8 billion RMB for the fiscal year 2023, projecting a growth of 20% compared to 2022[176]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2023, focusing on innovative medical technologies[176]. - The company plans to invest 500 million RMB in new technology development over the next three years[176]. - The company aims to strengthen its competitive position through potential mergers and acquisitions in the medical technology field[165]. - The company plans to expand its marketing network, focusing on emerging economies and establishing overseas marketing branches in key regions such as Europe, South Asia, and South America[134].